When you need ultimate precision and flexibility, you need some rather special equipment!

The latest requirements of both the FDA and European Medicines Agency Agency set very specific quantifiable limits for Nitrosamine detection. To maintain their role as the leader in this area, QUINTA-ANALYTICA are proud to announce the addition of the Thermo Fisher Scientific Q Exactive™ Focus Hybrid Quadrupole-Orbitrap™ Mass Spectrometer to their already considerable technology line-up.

Providing exceptional sensitivity and flexibility, this type of mass spectrometer truly sets the standard for screening, quantitation, identification, and confirmation of targeted and untargeted compounds. The Q Exactive Focus system delivers exceptional sensitivity which truly takes analysis and detection to the next level.

About the purchase, CCO Jiri Raska commented:

“For as long as the Nitro saga continues, and the FDA and EMA continue to set new detection guidelines, we will continue to invest in the very best technology so we can be absolutely certain we have the right equipment, and in-house skills, to deliver exactly what our partners need to be compliant and successful”.

You can read more about Quinta’s Nitrosamine services here.

Additional News

  • 25 March 2026

    ADC Webinar: DAR, Bioanalysis and Intact MS in Next-Generation ADC Development

    On behalf of Conscio Group, registration is now open for our free expert-led webinar on DAR characterization, bioanalytical strategy and mass spectrometry insight in ADC development.

  • 17 December 2025

    PF 2026: Thank You from Quinta-Analytica

    In 2025, Quinta-Analytica continued to turn complex development challenges into tangible progress. Our PF 2026 message looks back at key milestones and thanks the partners, clients, and teams who made them possible.

  • 15 December 2025

    IVBE for locally acting drugs: insights from Conscio Science Day in Munich

    Can bioequivalence for locally acting drugs be demonstrated without a single subject in a clinical trial? Yes, if your in vitro bioequivalence (IVBE) toolkit is set up in the right way.